Ki20227
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β) . Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction[1].
Product Specifications
CAS Number
623142-96-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Fms; c-Kit; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Ki20227.html
Concentration
10mM
Purity
99.51
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C=C1OC)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC(C)C4=NC=CS4
Molecular Formula
C24H24N4O5S
Molecular Weight
480.54
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NF kappa B (S276) (Nuclear factor of kappa light polypeptide gene enhancer in B Cells 3, Nuclear factor NF-kappa-B p65 subunit, Transcription factor p65, NFKB3, RELA) (PE)
NF kappa B (S276) (Nuclear factor of kappa light polypeptide gene enhancer in B Cells 3, Nuclear factor NF-kappa-B p65 subunit, Transcription factor p65, NFKB3, RELA) (PE)
Lentiviral human LRPPRC sgRNA gene knockout kit - Lentiviral human LRPPRC sgRNA gene knockout kit (25)